Treatment of Hypoparathyroidism with Parathyroid Hormone 1–34

  • Karen K. WinerEmail author
  • Gordon B. CutlerJr.


The clinical presentation of hypoparathyroidism includes inappropriately low or undetectable serum parathyroid hormone (PTH), hypocalcemia, hyperphosphatemia, and frequently, hypomagnesemia. Chronic symptoms include neuromuscular irritability causing tetany, muscle cramping, spasms, and seizures. In adults, the disorder is usually a complication of neck surgery due to an excision of a goiter or thyroid cancer. In children, the condition is most often due to inherited disorders such as autoimmune polyglandular failure syndrome type 1 (APS-1) or an activating mutation in the calcium-sensing receptor (CaSR). Children with hypoparathyroidism pose a particular therapeutic dilemma because recurrent episodes of hypocalcemia, if associated with seizures, may adversely affect brain development.


Parathyroid hormone Hypoparathyroidism Calcium receptor CaSR APS-1 PTH 1-34 Hypocalcemia 


  1. 1.
    Horowitz MJ, Stewart AF (2008) Hypoparathyroidism: is it time for replacement therapy? J Clin Endocrinol Metab 93(9):3307–3309CrossRefGoogle Scholar
  2. 2.
    Romijn JA, Smit JWA, Lamberts SW (2003) Intrinsic imperfections of endocrine replacement therapy. Eur J Endocrinol 149:91–97CrossRefPubMedGoogle Scholar
  3. 3.
    Rejnmark L, Sikjaer T, Underbjerg L, Mosekilde L (2013) PTH replacement therapy of hypoparathyroidism. Osteoporos Int 24:1529–1536CrossRefPubMedGoogle Scholar
  4. 4.
    Weber G, Cazzuffi MA, Frisone F, De Angelis M, Pasolini D, Tomaselli V et al (1998) Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1, 25-dihydrocholecalciferol. Child Nephrol Urol 9:273–276Google Scholar
  5. 5.
    Santos F, Smith MJ, Chan JC (1986) Hypercalciuria associated with long term administration of calcitriol (1.25- dihydroxyvitamin D). Am J Dis Child 140:139–142CrossRefPubMedGoogle Scholar
  6. 6.
    Winer KK, Yanovski JA, Cutler GB Jr (1996) Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial. JAMA 276:631–636CrossRefPubMedGoogle Scholar
  7. 7.
    Winer KK, Yanovsiki JA, Sarani B, Cutler GB Jr (1998) A randomized, crossover trial of once-daily versus twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480–3486PubMedGoogle Scholar
  8. 8.
    Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28(11):2277–2285CrossRefPubMedGoogle Scholar
  9. 9.
    Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97(12):4507–4514CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Mancilla EE, De Luca F, Ray K, Winer KK, Fan GF (1997) A Ca(2+) sensing receptor mutation causes hypoparathyroidism by increasing receptor sensitivity to CA2+ and maximal signal transduction. Pediatr Res 42(4):443–447CrossRefPubMedGoogle Scholar
  11. 11.
    Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV (1996) Familial Syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335(15):1115–1122CrossRefPubMedGoogle Scholar
  12. 12.
    Husebye ES, Perheentupa J, Rautemaa R, Kämpe O (2009) Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 265(5):514–529CrossRefPubMedGoogle Scholar
  13. 13.
    Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146(2):215–222CrossRefPubMedGoogle Scholar
  14. 14.
    Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney J Jr, Bilezikian JP (2013) The effect of PTH(1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98(6):2356–2361CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Collip JB (1925) The extraction of parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 63:395–438Google Scholar
  16. 16.
    Collip JB (1925) Clinical use of parathyroid hormone. Can Med Assoc J 15(11):1158PubMedCentralPubMedGoogle Scholar
  17. 17.
    Albirght F, Ellsworth R (1929) Studies on the physiology of the parathyroid glands; calcium and phosphorus studies on a case of idiopathic hypoparathyroidism. J Clin Invest 7(2):183–201CrossRefGoogle Scholar
  18. 18.
    Aurbach GD (1959) Isolation of parathyroid hormone after extraction with phenol. J Biol Chem 234:3179–3181PubMedGoogle Scholar
  19. 19.
    Melick RA, Gill JR Jr, Berson SA, Yalow RS, Bartter FC, Potts JT Jr, Aurbach GD (1967) Antibodies and clinical resistance to parathyroid hormone. N Engl J Med 276(3):144–147CrossRefPubMedGoogle Scholar
  20. 20.
    Brewer HB, Fairwell R, Ronan R, Sizemore GW, Arnaud CD (1972) Human parathyroid hormone amino acid sequence of the amino- terminal residues 1-34. Proc Natl Acad Sci U S A 69:3585–3588CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Niall HD, Sauer RT, Jacobs JW, Keutmann HT, Segre GV, O’Riordan JL, Aurbach GD, Potts JT Jr (1974) The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A 71(2):384–388CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Slovik D, Neer R, Potts J (1981) Short term effects of synthetic human parathyroid hormone on bone mineral metabolism in osteoporotic patients. J Clin Invest 68(5):1261–1271CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Slovik DM, Rosenthal DI, Doppelt SH, Potts JT, Daly MA, Campbell JA, Neer RM (1986) Restoration of spinal bone of osteoporotic men by treatment with human parathyroid hormone (1-34) and 1, 25-dihydroxyvitamin D. J Bone Miner Res 1(4):377–381CrossRefPubMedGoogle Scholar
  24. 24.
    Reeve J, Meunier P, Parson J, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trail. Br Med J 280:1340–1344CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Strogmann W, Bohrn E, Woloszczuk W (1990) First experiences in the substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone. Monatasschr Kinderheilkd 138:141–146Google Scholar
  26. 26.
    Chu NN, Li XN, Chen WL, Xu HR (2007) Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. Pharmazie 62(11):869–871PubMedGoogle Scholar
  27. 27.
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30(3):312–321CrossRefPubMedGoogle Scholar
  28. 28.
    Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone Neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32(4):426–438CrossRefPubMedGoogle Scholar
  29. 29.
    Vahle JL, Sato M, Long GG (2007) Variations in animal populations over time and differences in diagnostic thresholds used can impact tumor incidence data. Toxicol Pathol 35(7):1045–1046CrossRefPubMedGoogle Scholar
  30. 30.
    Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E (2007) Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 22(1):64–71CrossRefPubMedGoogle Scholar
  31. 31.
    Tashijan AH Jr, Gagel RF (2006) Teriparatide: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354–365CrossRefGoogle Scholar
  32. 32.
    Tashjian AH Jr, Golzman D (2008) Perspective on the interpretation of Rat carcinogenicity studies for human PTH 1-34 and human PTH 1–84. J Bone Miner Res 23(6):803–811CrossRefPubMedGoogle Scholar
  33. 33.
    Haseman JK, Hailey JR, Morris RW (1998) Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: a National Toxicology Program Update. Toxicol Pathol 26(3):428–441CrossRefPubMedGoogle Scholar
  34. 34.
    Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M (2008) Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 23(12):2033–2039CrossRefPubMedGoogle Scholar
  35. 35.
    Silverberg SJ, Shane E, Jacobs TP et al (1999) A 10 year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255CrossRefPubMedGoogle Scholar
  36. 36.
    Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr (2008) Effects of once-daily versus twice-daily parathyroid hormone 1-34 in children with hypoparathyroidism. J Clin Endocrinol Metab 93(9):3389–3395CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Winer KK, Ko CW, Reynolds J, Dowdy K, Keil M, Peterson D et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone 1–34 and calcitriol and calcium. J Clin Endocrinol Metab 88:4214–4220CrossRefPubMedGoogle Scholar
  38. 38.
    Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab 95(6):2680–2688CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS et al (2012) Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97(2):391–399CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Winer KK, Fulton K, Albert PS, Cutler GB Jr (2014) Twice-daily subcutaneous injections vs. pump delivery of PTH 1-34 in the Treatment of Children with Severe Congenital Hypoparathyroidism. J Pediatr 165(3):556–563.Google Scholar
  41. 41.
    Puig-Domingo M, Diaz G, Nicolau J, Fernandez C, Rueda S, Halperin I (2008) Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. Eur J Endocrinol 159:653–657CrossRefPubMedGoogle Scholar
  42. 42.
    Linglart A, Rothernbuhler A, Gueorgieva I, Lucchini P, Silve C, Bougneres P (2011) Long-term results of continuous subcutaneous recombinant PTH 1–34 infusion in children with refractory hypoparathyroidism. J Clin Endocrinol Metab 96(11):3308–3312CrossRefPubMedGoogle Scholar
  43. 43.
    Samuels MH, Veldhuis JD, Cawley C, Urban RJ, Luther M, Bauer R et al (1993) Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab 77(2):399–403PubMedGoogle Scholar
  44. 44.
    Harms HS, Kaptiana U, Kulpmann WR, Brabant G, Hesch RD (1989) Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J Clin Endocrinol Metab 69:843–851CrossRefPubMedGoogle Scholar
  45. 45.
    Cho YH, Tchan M, Roy B, Halliday R, Wilson M, Dutt S, Siew S, Munns C, Howard N (2012) Recombinant parathyroid hormone therapy for severe neonatal hypoparathyroidism. J Pediatr 160(2):345–348CrossRefPubMedGoogle Scholar
  46. 46.
    Newfield RS (2007) Recombinant PTH for initial management of neonatal hypocalcemia. N Engl J Med 356(16):1687–1688CrossRefPubMedGoogle Scholar
  47. 47.
    Mittleman SD, Hendy GN, Fefferman RA, Canaff L, Mosesova I, Cole DE, Burkett L, Geffner ME (2006) A Hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: successful treatment with recombinant human parathyroid hormone. J Clin Endocrinol Metab 91(7):2474–2479CrossRefGoogle Scholar
  48. 48.
    Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Women's Health Initiative Investigators (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669–683Google Scholar
  49. 49.
    Parfitt AM (1972) The interactions of thiazide Diuretics with parathyroid hormone and vitamin D studies in patients with hypoparathyroidism. J Clin Invest 51(7):1879–1888CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Middler S, Pak CY, Murad F, Bartter FC (1973) Thiazide diuretics and calcium metabolism. Metabolism 22(2):139CrossRefPubMedGoogle Scholar
  51. 51.
    Porter RH, Cox BG, Heaney D, Hostetter TH, Stinebaugh BJ, Suki WN (1978) Treatment of hypoparathyroid patients with chlorthalidone. N Engl J Med 298(11):577–581CrossRefPubMedGoogle Scholar
  52. 52.
    Eknoyan G, Suki WN, Martinez-Maldonado M (1970) Effect of diuretics on urinary excretion of phosphate, calcium and magnesium, in thyroparathyroidectomized dogs. J Lab Clin Med 76:257–266PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  1. 1.National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development/PGNBBethesdaUSA
  2. 2.Gordon Cutler Consultancy, LLCDeltavilleUSA

Personalised recommendations